DMPS-arsenic challenge test. II. Modulation of arsenic species, including monomethylarsonous acid (MMA(III)), excreted in human urine

Toxicology and Applied Pharmacology

Volumn 165, Issue 1, 2000, Pages 74-83

  Aposhian, H Vasken ^a   Zheng, Baoshan ^b   Aposhian, Mary M ^a   Le, X Chris ^c   Cebrian, Mariano E ^d   Cullen, William ^e   Zakharyan, Robert A ^a   Ma, Mingsheng ^c   Dart, Richard C ^f   Cheng, Zhai ^b,g   Andrewes, Paul ^e   Yip, Luke ^f   O'Malley, Gerald F ^f   Maiorino, Richard M ^a   Van Voorhies, Wayne ^a   Healy, Sheila M ^a   Titcomb, Allison ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b INSTITUTE OF GEOCHEMISTRY   (China)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DEPARTAMENTO DE FÍSICA   (Mexico)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Denver Metropol Med Response Syst   (United States)

^g CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic; Arsenic biotransformation; DMPS; MMA(III); Monomethylarsonous acid

Indexed keywords

ARSENIC; METHANEARSONIC ACID; UNITHIOL;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; INTOXICATION; LABORATORY DIAGNOSIS; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; URINARY EXCRETION;

EID: 0034657431     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2000.8922     Document Type: Article

References (36)

1. Aposhian H. V. DMSA and DMPS-water soluble antidotes for heavy metal poisoning. Annu. Rev. Pharmacol. Toxicol. 23:1983;193-215.
2. Aposhian H. V. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 37:1997;397-419.
3. Aposhian H. V., Aposhian M. M. Newer developments in arsenic toxicity. J. Am. Coll. Toxicol. 8:1989;1297-1305.
4. Aposhian H. V., Arroyo A., Cebrian M. E., Del Razo L. M., Hurlbut K. M., Dart R. C., Gonzalez-Ramirez D., Kreppel H., Speisky H., Smith A., Gonsebatt M. E., Ostrosky-Wegman P., Aposhian M. M. DMPS-arsenic challenge test. I. Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. J. Pharmacol. Exp. Ther. 282:1997a;192-200.
5. Aposhian H. V., Bruce D. C., Alter W., Dart R. C., Hurlbut K. M., Aposhian M. M. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: Correlation with dental amalgam score. FASEB J. 6:1992;2472-2476.
6. Aposhian H. V., Carter D. E., Hoover T. D., Hsu C.-A., Maiorino R. M., Stine E. DMSA, DMPS, and DMPA - as arsenic antidotes. Fundam. Appl. Toxicol. 4:1984;S58-S70.
7. Aposhian H. V., Maiorino R. M., Gonzalez-Ramirez D., Zuniga-Charles M., Xu Z., Hurlbut K. M., Junco-Munoz P., Dart R. C., Aposhian M. M. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 97:1995;23-38.
8. Aposhian, H. V., Zakharyan, R. A., Wildfang, E. K., Healy, S. M., Gailer, J., Radabaugh, T. R., Bogdan, G. M., Powell, L. A., and Aposhian, M. M.1999. How is inorganic arsenic detoxified. In Arsenic Exposure and Health Effects: Proceedings of the 3rd International Conference (W. R. Chappell, C. O. Abernathy, and R. L. Calderon, Eds.), pp. 289-297. Elsevier, New York.
9. Aposhian, H. V., Zakharyan, R. A., Wu, Y., Healy, S., and Aposhian, M. M.1997b. Enzymatic methylation of arsenic compounds. II. An overview. In Arsenic Exposure and Health Effects (C. O. Abernathy, R. L. Calderon, and W. R. Chappell, Eds.), pp. 296-321. Chapman & Hall, London.
10. Buchet J. P., Lauwerys R. Study of inorganic arsenic methylation by rat liver in vitro: Relevance for the interpretation of observations in man. Arch. Toxicol. 57:1985;125-129.
11. Cebrian M. E., Albores A., Aguilar M., Blakely E. Chronic arsenic poisoning in the north of Mexico. Hum. Toxicol. 2:1983;121-133.
12. Chatterjee A., Das D., Mandal B. K., Chowdhury T. R., Samanta G., Chakraborty D. Arsenic in ground water in six districts of West Bengal, India: The biggest arsenic calamity in the world. Part I. Arsenic species in drinking water and urine of the affected people. Analyst. 120:1995;643-650.
13. Chen C. J., Chuang Y. C., Lin T. M., Wu H. Y. Malignant neoplasms among residents of a Blackfoot disease-endemic area in Taiwan: High-arsenic artesian well water and cancers. Cancer Res. 45:1985;5895-5899.
14. Cullen W. R., McBride B. C., Manji H., Pickett A. W., Reglinski J. The metabolism of methylarsine oxide and sulfide. Appl. Organometal. Chem. 3:1989;71-78.
15. Cullen W. R., McBride B. C., Reglinski J. The reaction of methylarsenicals with thiols: Some biological implications. J. Inorg. Biochem. 21:1984;179-194.
16. Cullen W. R., Reimer K. J. Arsenic speciation in the environment. Chem. Rev. 89:1989;713-764.
17. Del Razo L. M., Arellano M. A., Cebrian M. E. The oxidation states of arsenic in well water from a chronic arsenic contaminated area of northern Mexico. Environ. Poll. 64:1990;143-153.
18. Goering P. L., Aposhian H. V., Mass M. J., Cebrian M., Beck B. D., Waalkes M. P. The enigma of arsenic carcinogenesis: Role of metabolism. Toxicol. Sci. 49:1999;5-14.
19. Gonzalez-Ramirez D., Zuniga-Charles M., Narro-Juarez A., Molina-Recio Y., Hurlbut K. M., Dart R. C., Aposhian H. V. DMPS (2,3-dimercaptopropane-1-sulfonate, Dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride. J. Pharmacol. Exp. Ther. 287:1998;8-12.
20. Hopenhayn-Rich C., Biggs M. L., Kalman D. A., Moore L. E., Smith A. H. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ. Health Perspect. 104:1996;1200-1207.
21. IARC, 1987, Monograph on the Evaluation of Carcinogenic Risks to Humans: Overall Evaluations of Carcinogenicity: An updating of IARC Monographs, Vol. 1 to 42., IARC, Lyon.
22. Kemper, F. H., Jekat, F. W., Bertram, H. P., and Eckard, R.1990. New chelating agents. In Basic Science in Toxicology, Proceedings of the 5th International Congress of Toxicology, Brighton, England 1989 (G. N. Volans, J. Sims, F. M. Sullivan, and P. Turner, Eds.), pp. 523-546. Taylor & Francis Ltd, London.
23. Le X. C., Ma M. Short-column liquid chromatography with hydride generation atomic fluorescence detection for the speciation of arsenic. Anal. Chem. 70:1998;1926-1933.
24. Maiorino R. M., Dart R. C., Carter D. E., Aposhian H. V. Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J. Pharmacol. Exp. Ther. 259:1991;808-814.
25. Mass M. J., Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: A model for a mechanism of carcinogenesis. Mutat. Res. 386:1997;263-277.
26. National Research Council Report, 1977, Medical and Biologic Effects of Environmental Pollutants: Arsenic, National Academy of Sciences, Washington, DC.
27. National Research Council (NRC) Report, 1999, Arsenic in Drinking Water, National Academy Press, Washington, DC.
28. Niu, S., Cao, S., and Shen, E.1997. The status of arsenic poisoning in China. In Arsenic: Exposure and Health Effects (C. O. Abernathy, R. L. Calderon, and W. R. Chappell, Eds.), pp. 78-83. Chapman & Hall, London.
29. III) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163:2000;203-207.
30. Styblo M., Delnomdedieu M., Thomas D. J. Mono- and dimethylation of arsenic in rat liver cytosol in vitro. Chem.-Biol. Interact. 99:1996;147-164.
31. Tseng C. H., Chong C. K., Chen C. J., Tai T. Y. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in Blackfoot Disease endemic villages in Taiwan. Atherosclerosis. 120:1996;125-133.
32. 12 and glutathione does not require an enzyme. Toxicol. Appl. Pharmacol. 154:1999a;287-291.
33. V reductase. Chem. Res. Toxicol. 12:1999b;1278-1283.
34. III) is the substrate for MMA methyltransferase of rabbit liver and human hepatocytes. Toxicol. Appl. Pharmacol. 158:1999;9-15.
35. Zakharyan R. A., Wu Y., Bogdan G. M., Aposhian H. V. Enzymatic methylation of arsenic compounds. Assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem. Res. Toxicol. 8:1995;1029-1038.
36. Zhao C. Q., Young M. R., Diwan B. A., Coogan T. P., Waalkes M. P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;10907-10912.